

09/821883  
03/30/01

ISSUE CLASSIFICATION	
Class	Subclass

O.I.P.E. SCANNED <i>KW</i> <i>PC4</i> Q.A. <i>TC</i>	PATENT DATE
---	-------------

APPLICATION NO. 09/821883	CONT/PRIOR D	CLASS 424	SUBCLASS 85-1	ART UNIT T642	EXAMINER RAWLENS
------------------------------	-----------------	--------------	------------------	------------------	---------------------

TITLE	APPLICANTS
1. <b>Chairman</b>	1. <b>Chairman</b>
2. <b>Vice Chairman</b>	2. <b>Vice Chairman</b>
3. <b>Secretary</b>	3. <b>Secretary</b>
4. <b>Treasurer</b>	4. <b>Treasurer</b>
5. <b>Member</b>	5. <b>Member</b>
6. <b>Member</b>	6. <b>Member</b>
7. <b>Member</b>	7. <b>Member</b>
8. <b>Member</b>	8. <b>Member</b>
9. <b>Member</b>	9. <b>Member</b>
10. <b>Member</b>	10. <b>Member</b>
11. <b>Member</b>	11. <b>Member</b>
12. <b>Member</b>	12. <b>Member</b>
13. <b>Member</b>	13. <b>Member</b>
14. <b>Member</b>	14. <b>Member</b>
15. <b>Member</b>	15. <b>Member</b>
16. <b>Member</b>	16. <b>Member</b>
17. <b>Member</b>	17. <b>Member</b>
18. <b>Member</b>	18. <b>Member</b>
19. <b>Member</b>	19. <b>Member</b>
20. <b>Member</b>	20. <b>Member</b>
21. <b>Member</b>	21. <b>Member</b>
22. <b>Member</b>	22. <b>Member</b>
23. <b>Member</b>	23. <b>Member</b>
24. <b>Member</b>	24. <b>Member</b>
25. <b>Member</b>	25. <b>Member</b>
26. <b>Member</b>	26. <b>Member</b>
27. <b>Member</b>	27. <b>Member</b>
28. <b>Member</b>	28. <b>Member</b>
29. <b>Member</b>	29. <b>Member</b>
30. <b>Member</b>	30. <b>Member</b>
31. <b>Member</b>	31. <b>Member</b>
32. <b>Member</b>	32. <b>Member</b>
33. <b>Member</b>	33. <b>Member</b>
34. <b>Member</b>	34. <b>Member</b>
35. <b>Member</b>	35. <b>Member</b>
36. <b>Member</b>	36. <b>Member</b>
37. <b>Member</b>	37. <b>Member</b>
38. <b>Member</b>	38. <b>Member</b>
39. <b>Member</b>	39. <b>Member</b>
40. <b>Member</b>	40. <b>Member</b>
41. <b>Member</b>	41. <b>Member</b>
42. <b>Member</b>	42. <b>Member</b>
43. <b>Member</b>	43. <b>Member</b>
44. <b>Member</b>	44. <b>Member</b>
45. <b>Member</b>	45. <b>Member</b>
46. <b>Member</b>	46. <b>Member</b>
47. <b>Member</b>	47. <b>Member</b>
48. <b>Member</b>	48. <b>Member</b>
49. <b>Member</b>	49. <b>Member</b>
50. <b>Member</b>	50. <b>Member</b>
51. <b>Member</b>	51. <b>Member</b>
52. <b>Member</b>	52. <b>Member</b>
53. <b>Member</b>	53. <b>Member</b>
54. <b>Member</b>	54. <b>Member</b>
55. <b>Member</b>	55. <b>Member</b>
56. <b>Member</b>	56. <b>Member</b>
57. <b>Member</b>	57. <b>Member</b>
58. <b>Member</b>	58. <b>Member</b>
59. <b>Member</b>	59. <b>Member</b>
60. <b>Member</b>	60. <b>Member</b>
61. <b>Member</b>	61. <b>Member</b>
62. <b>Member</b>	62. <b>Member</b>
63. <b>Member</b>	63. <b>Member</b>
64. <b>Member</b>	64. <b>Member</b>
65. <b>Member</b>	65. <b>Member</b>
66. <b>Member</b>	66. <b>Member</b>
67. <b>Member</b>	67. <b>Member</b>
68. <b>Member</b>	68. <b>Member</b>
69. <b>Member</b>	69. <b>Member</b>
70. <b>Member</b>	70. <b>Member</b>
71. <b>Member</b>	71. <b>Member</b>
72. <b>Member</b>	72. <b>Member</b>
73. <b>Member</b>	73. <b>Member</b>
74. <b>Member</b>	74. <b>Member</b>
75. <b>Member</b>	75. <b>Member</b>
76. <b>Member</b>	76. <b>Member</b>
77. <b>Member</b>	77. <b>Member</b>
78. <b>Member</b>	78. <b>Member</b>
79. <b>Member</b>	79. <b>Member</b>
80. <b>Member</b>	80. <b>Member</b>
81. <b>Member</b>	81. <b>Member</b>
82. <b>Member</b>	82. <b>Member</b>
83. <b>Member</b>	83. <b>Member</b>
84. <b>Member</b>	84. <b>Member</b>
85. <b>Member</b>	85. <b>Member</b>
86. <b>Member</b>	86. <b>Member</b>
87. <b>Member</b>	87. <b>Member</b>
88. <b>Member</b>	88. <b>Member</b>
89. <b>Member</b>	89. <b>Member</b>
90. <b>Member</b>	90. <b>Member</b>
91. <b>Member</b>	91. <b>Member</b>
92. <b>Member</b>	92. <b>Member</b>
93. <b>Member</b>	93. <b>Member</b>
94. <b>Member</b>	94. <b>Member</b>
95. <b>Member</b>	95. <b>Member</b>
96. <b>Member</b>	96. <b>Member</b>
97. <b>Member</b>	97. <b>Member</b>
98. <b>Member</b>	98. <b>Member</b>
99. <b>Member</b>	99. <b>Member</b>
100. <b>Member</b>	100. <b>Member</b>

Reiner Laus  
Dimitar Vidovic  
Thomas Graddis

## Compositions and methods for dendritic cell-based immunotherapy

PTO-2040  
12/99[illegible]

<input type="checkbox"/> <b>TERMINAL DISCLAIMER</b>	<b>DRAWINGS</b>			<b>CLAIMS ALLOWED</b>	
	<b>Sheets Drwg.</b>	<b>Figs. Drwg.</b>	<b>Print Fig.</b>	<b>Total Claims</b>	<b>Print Claim for O.G.</b>
<input type="checkbox"/> The term of this patent subsequent to _____ (date) has been disclaimed.  <input type="checkbox"/> The term of this patent shall not extend beyond the expiration date of U.S Patent. No. _____  _____	_____ (Assistant Examiner)			<b>NOTICE OF ALLOWANCE MAILED</b>	
	_____ (Primary Examiner)			<b>ISSUE FEE</b>	
				<b>Amount Due</b>	<b>Date Paid</b>
<input type="checkbox"/> The terminal ____months of this patent have been disclaimed.	_____ (Legal Instruments Examiner)			<b>ISSUE BATCH NUMBER</b>	

The information disclosed herein may be restricted. Unauthorized disclosure may be prohibited by the United States Code Title 35, Sections 122, 181 and 368. Reproduction outside the U.S. Patent & Trademark Office is restricted to authorized employees and contractors only.

FILED WITH: ☐ DISK (CRF) ☐ FICHE ☐ CD-ROM  
(Attached in pocket on right inside flap)

**BEST AVAILABLE COPY**

(FACE)